Yahoo
NasdaqCM - BOATS Real Time Price USD

Century Therapeutics, Inc. (IPSC)

2.4450 +0.1450 (+6.30%)
At close: April 22 at 4:00:01 PM EDT
2.4200 -0.0250 (-1.02%)
Overnight: 1:49:30 AM EDT
Trade IPSC on Coinbase
Chart Range Bar
Loading chart for IPSC
Chart does not reflect overnight price.
  • Previous Close 2.3000
  • Open 2.3100
  • Bid 2.4200 x 400
  • Ask 2.4600 x 400
  • Day's Range 2.3100 - 2.4450
  • 52 Week Range 0.4350 - 3.0400
  • Volume 1,015,641
  • Avg. Volume 1,354,919
  • Market Cap (intraday) 439.422M
  • Beta (5Y Monthly) 1.67
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1400
  • Earnings Date (est.) May 14, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.00

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

www.centurytx.com

78

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: IPSC

Trailing total returns as of 4/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IPSC
145.73%
S&P 500 (^GSPC)
4.27%

1-Year Return

IPSC
352.78%
S&P 500 (^GSPC)
34.99%

3-Year Return

IPSC
19.57%
S&P 500 (^GSPC)
72.68%

5-Year Return

IPSC
87.46%
S&P 500 (^GSPC)
72.62%

Earnings Trends: IPSC

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -19.17M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

0
50M
100M

Analyst Insights: IPSC

View More

Analyst Price Targets

2.00 Low
3.00 Average
2.4450 Current
4.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/21/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 2 -> 5

Statistics: IPSC

View More

Valuation Measures

Annual
As of 4/22/2026
  • Market Cap

    438.52M

  • Enterprise Value

    364.97M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.93

  • Price/Book (mrq)

    2.76

  • Enterprise Value/Revenue

    3.34

  • Enterprise Value/EBITDA

    140.65

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.78%

  • Return on Assets (ttm)

    -3.26%

  • Return on Equity (ttm)

    -5.98%

  • Revenue (ttm)

    109.16M

  • Net Income Avi to Common (ttm)

    -9.58M

  • Diluted EPS (ttm)

    -0.1400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    117.11M

  • Total Debt/Equity (mrq)

    27.41%

  • Levered Free Cash Flow (ttm)

    -97.21M

Compare To: IPSC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: IPSC

Fair Value

2.4450 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: